Ranbaxy recalls generic Lipitor in US
- Essar Leaks: SC issues notices to Essar Group and Centre on PIL seeking court-monitored probe
- Karnataka CM announces CBI probe into death of IAS officer DK Ravi
- Hashimpura massacre: 10 freed still in UP Police
- Jaitley, Rajan paper over the cracks, minister says in regular, frank talks
- Lee Kuan Yew, founder of modern Singapore, passes away at 91
At present, the company is in the process of settling issue with the USFDA which in 2008 banned import of 30 generic drugs manufactured at its facilities at Dewas (Madhya Pradesh), and Paonta Sahib and Batamandi units in Himachal Pradesh for gross violation of manufacturing norms.
In January this year, the US Justice Department sought a permanent injunction against Ranbaxy, a move that required the Indian pharmaceutical major to make fundamental changes at its plants both in the US and India.
In December 2011, Ranbaxy had filed a consent decree with a US court as part of its settlement with the American authorities and said it had earmarked up to USD 500 million for settlement with the US authorities.
Ranbaxy's dosage forms facility at Mohali was approved by the US Food and Drug Administration (FDA) in October 2011.
Japanese drug-maker Daiichi Sankyo had acquired majority stake in Ranbaxy in 2008 for a total outgo of around Rs 22,000 crore.
Stocks More on Ranbaxy
Company INFO More on Ranbaxy
Ranbaxy recalls generic Lipitor from the US market
(Reuters) Laboratories Ltd has voluntarily recalled its cholesterol-lowering drug atorvastatin in the United States, a development that could dent its image further in the world's biggest prescription drug market where the company faced an earlier ban. Ranbaxy did not specify the reason for the recall of the drug, which largely drove the company's sales in the first of half the year. Shares of the company fell more than 4 percent following the announcement.
The recall of atorvastatin, a generic version of Pfizer Inc's Lipitor, will temporarily disrupt supplies in the US market while the company conducts an investigation that is expected to take two weeks, it said. Lipitor is considered as the world's best-selling drug ever and at its peak generated $13 billion in one year for Pfizer.Ranbaxy was the first company to launch generic Lipitor inthe United States after Pfizer's patent expired last year.